1stOncology™: Cancer Intelligence Service – Page 14727 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

ISA Pharmaceuticals Promotes Gerben Moolhuizen to Chief Executive Officer

On May 23, 2018 ISA Pharmaceuticals B.V., a clinical-stage immune oncology company, reported that Gerben Moolhuizen has been promoted from Chief Business Officer to Chief Executive Officer, effective June 1, 2018 (Press release, ISA Pharmaceuticals, MAY 23, 2018, View Source [SID1234526856]). He takes over the position from Ronald Loggers, who has served as ISA Pharmaceuticals´ CEO since 2013.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

"We would like to thank Ronald Loggers for his leadership during the past five years and his contribution in developing ISA Pharmaceuticals into a leading European immuno-oncology player," said Bart Bergstein, Chairman of ISA´s Board of Directors. "We look forward to further advancing ISA´s pipeline and commercial reach and are delighted that Gerben Moolhuizen, who played a key role in closing ISA´s latest deal with Regeneron, will take over as CEO."

With over twenty years of experience in the pharmaceutical and biotechnology industry, Gerben Moolhuizen has a strong track record in various management roles covering business development, product development and general management. His experience spans diverse fields and a broad array of technologies (biopharmaceuticals, small molecules, drug delivery, pharmaceutical development and manufacturing, diagnostics, vaccines, and generics). From January 2016 to May 2018, Gerben Moolhuizen served as ISA Pharmaceuticals´ Chief Business Officer (CBO).

"I am excited about my appointment as ISA´s CEO," said Gerben Moolhuizen. "Over the last years, ISA has significantly matured to a company with strong clinical data and respected pharma partners. We are now looking forward to further advancing our clinical pipeline and to pursuing new business opportunities."

Gerben Moolhuizen holds an M.Sc. from Utrecht University in Medical Biology and an MBA from Erasmus University Rotterdam. Prior to his involvement with ISA Pharmaceuticals, he was General Manager at OctoPlus B.V. and has been closely involved in the company´s fundraising activities, its IPO, and the acquisition by Dr. Reddy’s. Moreover, he has also been responsible for the subsequent integration of OctoPlus into Dr. Reddy’s R&D organization. Prior to OctoPlus, Gerben Moolhuizen worked, among others, at Pharming N.V., where he held various roles in business development and product development.

Johnson & Johnson to Participate in the Jefferies 2018 Global Healthcare Conference

On May 23, 2018 Johnson & Johnson (NYSE: JNJ) reported it will participate in the Jefferies 2018 Global Healthcare Conference on Wednesday, June 6, at the Grand Hyatt, New York (Press release, Johnson & Johnson, MAY 23, 2018, View Source [SID1234526853]). Dominic Caruso, Executive Vice President, Chief Financial Officer will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time).

Lupagen & Humanigen to explore point-of-care CAR-T therapy

On May 22, 2018 Lupagen, Inc. (www.lupagen.com), a medical device company developing first-in-class cell and gene therapy delivery technologies for CAR-T, gene editing and immunotherapy products, reported the intent to explore the development of a bedside, point-of-care delivered CAR-T therapy with Humanigen, Inc. (OTCQB: HGEN), a biopharmaceutical company developing cutting-edge CAR-T optimization and oncology treatments (Press release, Lupagen, MAY 22, 2018, View Source;humanigen-to-explore-point-of-care-car-t-therapy-300652016.html [SID1234573190]).

Lupagen and Humanigen are planning work to investigate the potential of a bedside CAR-T therapy created from Humanigen’s Ifabotuzumab, a first-in-class, monoclonal antibody targeting the EphA3 receptor tyrosine kinase.

"We are excited to support Humanigen’s strategic objectives to deliver safer, more effective and more routine CAR-T treatments, including one with the novel EphA3 target," said Nipon Das, M.D., chief executive officer and co-founder of Lupagen. "A bedside, closed-loop, point-of-care patient-connected system allows patient cells to be harvested, reprogrammed or modified, then reinfused at the bedside. The potential positive impact on CAR-T and other ex-vivo autologous cell and gene therapies is enormous through lower treatment costs, increased patient access and enhanced safety and control of these powerful new therapies."

10-K – Annual report [Section 13 and 15(d), not S-K Item 405]

Burzynski Research Institute has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission .

10-K – Annual report [Section 13 and 15(d), not S-K Item 405]

Burzynski Research Institute has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Burzynski Research Institute, 2018, MAY 22, 2018, View Source [SID1234526849]).